Carson Advisory Inc. Sells 1,718 Shares of Pfizer Inc. (NYSE:PFE)

Carson Advisory Inc. cut its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 8.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,241 shares of the biopharmaceutical company’s stock after selling 1,718 shares during the quarter. Carson Advisory Inc.’s holdings in Pfizer were worth $506,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Harbour Investments Inc. increased its position in shares of Pfizer by 6.1% during the 3rd quarter. Harbour Investments Inc. now owns 61,216 shares of the biopharmaceutical company’s stock valued at $2,031,000 after purchasing an additional 3,507 shares during the last quarter. Financial Gravity Asset Management Inc. increased its holdings in Pfizer by 812.2% during the third quarter. Financial Gravity Asset Management Inc. now owns 4,570 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 4,069 shares during the last quarter. OLD National Bancorp IN raised its position in Pfizer by 26.2% in the third quarter. OLD National Bancorp IN now owns 200,937 shares of the biopharmaceutical company’s stock worth $6,665,000 after acquiring an additional 41,679 shares during the period. Tompkins Financial Corp grew its position in shares of Pfizer by 4.2% during the 3rd quarter. Tompkins Financial Corp now owns 39,236 shares of the biopharmaceutical company’s stock valued at $1,301,000 after acquiring an additional 1,594 shares during the period. Finally, Brown Shipley& Co Ltd lifted its stake in Pfizer by 3.6% in the third quarter. Brown Shipley& Co Ltd now owns 21,200 shares of the biopharmaceutical company’s stock valued at $703,000 after purchasing an additional 746 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.63 during trading on Wednesday, hitting $28.35. The company had a trading volume of 26,990,295 shares, compared to its average volume of 40,022,254. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The stock’s 50-day moving average is $28.18 and its two-hundred day moving average is $27.71. The stock has a market capitalization of $160.65 billion, a price-to-earnings ratio of -469.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 EPS. As a group, analysts predict that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 5.93%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $35.54.

Get Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.